• Molecular NameCeftazidime
  • SynonymNA
  • Weight547.593
  • Drugbank_IDDB00438
  • ACS_NO72558-82-8
  • Show 3D model
  • LogP (experiment)-1.6
  • LogP (predicted, AB/LogP v2.0)-2.82
  • pka1.9, 2.7, 4.1
  • LogD (pH=7, predicted)-6.32
  • Solubility (experiment)0.396 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.23
  • LogSw (predicted, AB/LogsW2.0)7.12
  • Sw (mg/ml) (predicted, ACD/Labs)156.09
  • No.of HBond Donors5
  • No.of HBond Acceptors13
  • No.of Rotatable Bonds9
  • TPSA241.93
  • StatusFDA approved
  • AdministrationIntravenous, intramuscular
  • PharmacologyA third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negative bacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections.
  • Absorption_value0.0
  • Absorption (description)Ceftazidime is not absorbed by oral administration but is given by injection as its sodium salt or in solution with arginine.
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding21.0
  • Volume of distribution (VD)0.23 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmnegligible
  • Half life1.6 h
  • ExcretionThe drug crosses the placenta and is distributed into breast milk. It is passively excreted in bile, although only a small proportion is eliminated by this route. The drug is mainly excreted by the kidneys, almost exclusively by glomerular filtration. About 80 to 90% of a dose is recovered unchanged in urine in 24 h as it does not undergo metabolism. It is removed by haemodialysis and peritoneal dialysis. There is no evidence of accumulation of the drug in serum after multiple dosing.
  • Urinary Excretion84
  • Clerance1.05CLcr + 0.12 ml/min/kg; 115 mL/min; serum, 98 to 122 mL/min (healthy individuals); 142 to 376 mL/min/1.73m2 for patients suffering with cystic fibrosis; 79 mL/min for geriatric patients aged between 63 and 83 years.
  • ToxicityCeftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A